Chemical Nameevinacumab-dgnb
Dosage FormInjection (intravenous; 345 mg/2.3 mL (150 mg/mL), 1,200 mg/8 mL (150 mg/mL))
Drug ClassInhibitors
CompanyRegeneron Pharmaceuticals
Approval Year2021


  • Indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia
Last updated on 2/24/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Evkeeza (evinacumab-dgnb) Prescribing Information2021Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Document TitleYearSource
Evinacumab for homozygous familial hypercholesterolemia.2020The New England Journal of Medicine